
Sevasemten: Servier provides update on studies in Duchenne and Becker muscular dystrophy
Servier has announced that it will discontinue the development of sevasemten for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) following the result of clinical studies. The company reported that the studies did not demonstrate sufficient benefit to support continued development of the programme. According to Servier, no new safety concerns were identified during the studies and the safety profile remained consistent with previous research.
Servier has indicated that further analysis of the data will continue and that additional findings will be shared with both the scientific and patient communities as they become available.
You can read the Servier community letter here:
If you have any questions or concerns about your treatment, please speak with your specialist Duchenne care team. If you would like a wider conversation following this news, please give us a call on 0300 102 1762 or email us at support@actionduchenne.org. If you have any questions about the science, research, or the information shared in this update, please feel free to contact our Science Team at science@actionduchenne.org, who will be happy to support you.
We recognise that treatment updates can sometimes feel worrying. If you have concerns, your specialist clinical team remains the best source of advice for your individual circumstances.


